MENU
+Compare
ARKG
ETF ticker: BATS
AS OF
Jan 17 closing price
Price
$24.11
Change
-$0.14 (-0.58%)
Net Assets
1.1B

ARKG stock forecast, quote, news & analysis

Category: @Health
ARKG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for ARKG with price predictions
Jan 08, 2025

ARKG in -2.25% downward trend, falling for three consecutive days on January 08, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ARKG declined for three days, in of 301 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 75 cases where ARKG's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

ARKG broke above its upper Bollinger Band on January 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 03, 2025. You may want to consider a long position or call options on ARKG as a result. In of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ARKG just turned positive on January 03, 2025. Looking at past instances where ARKG's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

ARKG moved above its 50-day moving average on January 03, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ARKG crossed bullishly above the 50-day moving average on January 08, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in of 314 cases, the price rose further within the following month. The odds of a continued upward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are NVIDIA Corp (NASDAQ:NVDA), Amgen (NASDAQ:AMGN), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exact Sciences Corp (NASDAQ:EXAS), Teladoc Health (NYSE:TDOC), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.

Market Cap

The average market capitalization across the ARK Genomic Revolution ETF ETF is 96.19B. The market cap for tickers in the group ranges from 21.43M to 3.37T. NVDA holds the highest valuation in this group at 3.37T. The lowest valued company is SNTI at 21.43M.

High and low price notable news

The average weekly price growth across all stocks in the ARK Genomic Revolution ETF ETF was -2%. For the same ETF, the average monthly price growth was 6%, and the average quarterly price growth was -4%. MASS experienced the highest price growth at 32%, while PACB experienced the biggest fall at -22%.

Volume

The average weekly volume growth across all stocks in the ARK Genomic Revolution ETF ETF was -17%. For the same stocks of the ETF, the average monthly volume growth was -29% and the average quarterly volume growth was 3%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 84
Price Growth Rating: 60
SMR Rating: 89
Profit Risk Rating: 88
Seasonality Score: 4 (-100 ... +100)
View a ticker or compare two or three
ARKG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
ARK ETF Trust155 West 19th Street, 5th FloorNew York
Phone
212-426-7040
Web
www.ark-funds.com